- Home
- EGHT vs GOSS Comparison
EGHT vs GOSS Comparison
Compare EGHT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGHT
- GOSS
- Stock Information
- Founded
- EGHT 1987
- GOSS 2015
- Country
- EGHT United States
- GOSS United States
- Employees
- EGHT N/A
- GOSS N/A
- Industry
- EGHT EDP Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EGHT Technology
- GOSS Health Care
- Exchange
- EGHT Nasdaq
- GOSS Nasdaq
- Market Cap
- EGHT 250.2M
- GOSS 230.8M
- IPO Year
- EGHT 1997
- GOSS 2019
- Fundamental
- Price
- EGHT $1.84
- GOSS $0.98
- Analyst Decision
- EGHT Buy
- GOSS Strong Buy
- Analyst Count
- EGHT 6
- GOSS 5
- Target Price
- EGHT $2.83
- GOSS $9.20
- AVG Volume (30 Days)
- EGHT 899.3K
- GOSS 939.3K
- Earning Date
- EGHT 10-30-2024
- GOSS 11-07-2024
- Dividend Yield
- EGHT N/A
- GOSS N/A
- EPS Growth
- EGHT N/A
- GOSS N/A
- EPS
- EGHT N/A
- GOSS N/A
- Revenue
- EGHT $723,565,000.00
- GOSS $95,842,000.00
- Revenue This Year
- EGHT $0.85
- GOSS N/A
- Revenue Next Year
- EGHT $2.15
- GOSS N/A
- P/E Ratio
- EGHT N/A
- GOSS N/A
- Revenue Growth
- EGHT N/A
- GOSS N/A
- 52 Week Low
- EGHT $1.51
- GOSS $0.45
- 52 Week High
- EGHT $3.92
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- EGHT 43.68
- GOSS 50.68
- Support Level
- EGHT $1.89
- GOSS $0.98
- Resistance Level
- EGHT $2.20
- GOSS $1.09
- Average True Range (ATR)
- EGHT 0.11
- GOSS 0.06
- MACD
- EGHT -0.01
- GOSS -0.00
- Stochastic Oscillator
- EGHT 16.67
- GOSS 26.14
About EGHT 8x8 Inc
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.